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Abstract
The majority of patients with pancreatic ductal adenocarcinoma (PDA) develop metastatic disease 
after resection of their primary tumor. We found that livers from patients and mice with PDA 
harbor single, disseminated cancer cells (DCCs) lacking expression of cytokeratin-19 (CK19) and 
major histocompatibility complex class I (MHCI). We created a mouse model to determine how 
these DCCs develop. Intra-portal injection of immunogenic PDA cells into pre-immunized mice 
seeded livers only with single, non-replicating DCCs that were CK19- and MHCI-. The DCCs 
exhibited an endoplasmic reticulum (ER) stress response but, paradoxically lacked both inositol-
requiring enzyme 1α activation and expression of the spliced form of transcription factor XBP1 
(XBP1s). Inducible expression of XBP1s in DCCs, in combination with T cell-depletion, 
stimulated the outgrowth of macro-metastatic lesions that expressed CK19 and MHCI. Thus, 
unresolved ER stress enables DCCs to escape immunity and establish latent metastases.
Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cause of death from 
cancer worldwide (1), and has a five year survival rate of 6% (2). The majority of patients 
are diagnosed after the disease has spread beyond the primary tumor site. Patients who show 
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no clinical evidence of local invasion or distant metastasis are treated by surgery but 
approximately 75% of these patients develop metastatic disease within two years after 
resection of their primary tumors (3, 4), despite intra-operative examination of the liver 
confirming the absence of macro-metastatic lesions (5). These observations lead to the 
conclusion that latent metastases, detectable only microscopically, were present in these 
patients at the time of surgery and were responsible for the post-operative development of 
metastatic disease.
Latent metastases are thought to be lesions in which cancer cell proliferation is balanced by 
immune-mediated cancer cell death (6–8). A more recent hypothesis highlights the role of 
quiescent, single disseminated cancer cells (DCCs) (9–11). Single, non-replicating DCCs 
have been observed in several cancer types, most often in the bone marrow (12, 13), but 
whether quiescence is enforced by the microenvironment or is cancer cell-autonomous is not 
known (14). Immunity, both innate (15) and adaptive (7, 16, 17), also is likely to have a role 
in the selection and/or maintenance of latent DCCs. This has long been suspected based on 
the clinical observation that immunosuppressed recipients of allografts occasionally present 
with donor-derived cancer (18, 19). However, there is an unexplained paradox of immunity 
preventing the outgrowth of latent metastases while not eliminating latent metastases.
In the present study, we examine the nature of latent metastases in PDA by developing a 
mouse model that replicates the characteristics of hepatic DCCs that are found in human 
PDA and in spontaneously arising PDA in mice. We studied the metastatic process in the 
context of an ongoing adaptive immune response because of the occurrence of cancer cell-
specific immunity in human and mouse PDA (20–23).
Results
Quiescent, single disseminated cancer cells in the livers of human and mice with PDA.
To determine whether hepatic DCCs occur in human PDA, we microscopically examined 
tissue sections from the primary tumors and livers of five patients with PDA who had no 
clinically detectable hepatic metastases. The clinicopathologic characteristics of the patients 
are shown in table S1. The tumors were genotyped as having p53 loss-of-heterozygosity, 
which permitted staining for mutant p53 accumulation as an identifier of cancer cells (24). 
p53+ cancer cells were present in both the primary tumors and livers of all five patients. The 
p53+ cancer cells resided in the livers as single cells that were consistently CK19-, Ki67-, 
and MHCI-, in contrast to the cancer cells in the primary tumors, which exhibited all three 
markers (Fig. 1A–C). We also examined the livers from mice bearing the autochthonous 
LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre; RosaYFP (KPCY) model of PDA (25–27), 
which recapitulates human PDA. In livers devoid of macro-metastases, we found both 
yellow fluorescent protein (YFP)+ micro-metastases and DCCs. While the micro-metastases 
always expressed CK19, Ki67 and MHCI, the single DCCs were mainly CK19- (32/40), 
Ki67- (22/22), and MHCI- (28/28) (Fig.1D-F). Therefore, the livers of patients and mice 
with PDA contain DCCs that share an unusual phenotype linking the loss of epithelial gene 
expression and quiescence with a potential for escape from T cell recognition.
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A mouse model of hepatic metastasis in the context of an adaptive immune response
The absence of expression of MHCI on DCCs and the presence of cancer-specific CD8+ T 
cells in the genetically engineered mice model of PDA (20) and possibly in patients with 
PDA (28) suggested that DCCs may be selected by an anti-cancer immune response during 
the metastatic process. Accordingly, we developed a mouse model of hepatic metastases that 
allowed us to assess the effect of a pre-existing immune response. The mM1 (mouse 
metastasis 1) cell line was derived from a spontaneous liver metastasis of a mouse bearing 
an autochthonous PDA, and was stably transfected with a transposon vector directing the 
expression of diphtheria toxin receptor (DTR), Herpes simplex thymidine kinase (HSV-TK), 
firefly luciferase, and mTagBFP2 to generate mM1DTLB cells. Syngeneic C57Bl/6 mice 
were injected subcutaneously with 106 mM1DTLB cells, tumors were grown for 14 days, 
and then eliminated by treatment with diphtheria toxin (DTx) and ganciclovir (GcV). These 
“pre-immunized” mice and naïve mice were challenged by intra-splenic injections of 106 
mM1DTLB cells, followed by splenectomy, thereby seeding the liver via the portal vein, as 
in PDA (Fig. 2A).
We found that in naïve mice, whole body bioluminescence increased from day 1 after 
injection, consistent with the growth of hepatic metastases. In pre-immunized mice, 
however, whole body bioluminescence decreased after day 1, and by day 7 luminescence 
was at background levels (Fig. 2B, C). In additional cohorts of naïve and pre-immunized 
mice, livers were removed at intervals after the intra-splenic injection of mM1DTLB cells, 
and assessed for bioluminescence. Both photon flux (Fig. 2B) and visually detectable 
metastases increased in the livers of naïve mice between days 5 and 20, while metastatic foci 
were barely detectable in pre-immunized mice at day 5, and were absent at later time points 
(Fig. 2D). A potential role for T cells in the elimination of mM1DTLB cancer cells was 
suggested by the finding that in the livers of pre-immunized mice, tumor cells were 
frequently surrounded by both CD8+ and CD8- CD3+ T cells by 24h (Fig. S2A). This 
possibility was confirmed by treating pre-immunized mice with depleting antibodies to CD4 
and CD8, alone or together, or with isotype control antibody (Fig. S2B). Depleting either 
CD4+ or CD8+ T cells abrogated the ability of pre-immunization to suppress the 
development of macro-metastases (Fig. S2B), confirming this role of T cells.
Microscopic examination of livers from naïve and pre-immunized mice revealed the 
presence of macro-metastatic lesions in the former, but only single DCCs in the latter. The 
DCCs differed from cancer cells in the macro-metastases in the following ways: they did not 
express the epithelial markers CK19 and E-cadherin (Ecad), they did not express Ki67, they 
did not incorporate 5-ethynyl-2’-deoxyuridine (EdU), and they did not express MHCI (Fig. 
2E-I). Importantly, the phenotype of the DCCs in this metastasis model is similar to that of 
DCCs in human PDA and the KPCY mouse. T cells in the vicinity of DCCs were infrequent, 
whereas they surrounded macro-metastatic lesions in naïve mice (Fig. 2J). The absence of 
CK19 and Ecad expression did not indicate an epithelial-mesenchymal transition (EMT) 
because DCCs did not express the EMT markers desmin, αSMA, Snail1, or Slug (Fig. S3).
When naïve and pre-immunized mice were challenged with mM1DTLB cells via the tail 
vein, lung macro-metastases developed only in the naïve mice, whereas CK19- DCCs were 
observed in the lungs of pre-immunized mice (Fig. S4). We also assessed the 1242 cell line 
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derived from a primary PDA tumor of a KPC mouse (29), which had been modified with the 
same transposon vector, for its ability to generate DCCs. When naïve and pre-immunized 
mice were challenged by intra-splenic injection of 1242DTLB cells, hepatic macro-
metastases developed in the naïve mice, whereas only CK19- DCCs were observed in the 
livers of pre-immunized mice (Fig. S5). To assess more stringently the proliferation of 
DCCs, we labelled the mM1DTLB cells with CFSE before intra-splenic injection into naïve 
or pre-immunized mice. Whereas all cancer cells in the macro-metastases of naïve mice had 
become CFSE-, DCCs in pre-immunized mice had retained CFSE (Fig. S6A). Mice that had 
received intra-splenic injections of mM1DTLB cells were also given EdU in the drinking 
water for 20 days. While cancer cells in macro-metastases in naïve mice had incorporated 
EdU, almost all DCCs in pre-immunized mice were EdU- (Fig. S6B) indicating the absence 
of proliferation. Therefore, the occurrence of quiescent, MHCI- DCCs in the absence of 
macro-metastases is a consequence of an ongoing cancer-specific immune response.
A latent capacity for outgrowth of DCCs is controlled by T cells.
We next examined whether a latent capacity of DCCs for outgrowth into macro-metastatic 
lesions might be revealed by T cell depletion. When depleting anti-CD4 and anti-CD8 
antibodies were administered to pre-immunized mice three weeks after the establishment of 
DCCs, macro-metastases appeared in 10 of 15 mice. When T cells were depleted at nine 
weeks, macro-metastases appeared in 2 of 15 mice (Fig. 3). The metastases were composed 
of cancer cells that had re-expressed CK19 and MHCI, suggesting that DCCs revert to an 
epithelial phenotype to initiate the formation of macro-metastases. The lower frequency of 
macro-metastases in mice in which T cells were depleted at nine weeks suggests that DCCs 
with a capacity for reversion had decreased between three and nine weeks. Indeed we found 
that livers of pre-immunized mice have fewer DCCs at nine weeks than at three weeks (Fig. 
S7A). This loss of DCCs may reflect the killing by T cells of spontaneous revertants, as 
suggested by the occasional occurrence of a CK19+ DCC surrounded by T cells in the pre-
immunized mice (Fig. S7B). The re-expression of MHCI by these growing metastases also 
suggests the means by which T cells control the outgrowth of spontaneously reverting 
DCCs. To demonstrate that T cells alone are both necessary and sufficient for controlling the 
growth of MHCI- DCCs, we depleted NK cells by administering anti-NK1.1 antibody at the 
time of mM1DTLB cell challenge. Pre-immunized mice lacking NK cells were 
indistinguishable, with respect to the occurrence of DCCs and absence of macro-metastases, 
from control antibody-treated mice (Fig. S8). This evidence for a dominant role of the T cell 
in controlling DCCs is supported by the finding that DCCs were never seen to be in contact 
with CD45+ (Fig. S9A), F4/80+ (Fig. S9B), CD19+ (Fig. S9C), CD31+ (Fig. S9D), αSMA+ 
(Fig. S9E) or Ly-6G+ (Fig. S9F) cells, the distribution of these cell types being similar to 
that in the normal liver (Fig. S9 G-N).
A rare sub-population of PDA cells in vitro with the phenotype of DCCs
The absence of MHCI expression by DCCs raised the possibility that these cells were 
present in the injected PDA population and were negatively selected by T cells. Indeed, 
approximately 1% of the mM1DTLB cells in tissue culture were Ecad- and CK19-, and all 
Ecad- cells were MHCI- (Fig. 4A, B). The Ecad- cells resided in a non-proliferating sub-
population of cells, as indicated by the resistance of these HSV-TK-expressing cells to GcV 
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(Fig. 4C). A phenotypic plasticity of the mM1DTLB cells was shown by culturing FACS-
purified Ecad+ and Ecad- cells for three days, and finding that they generated Ecad- and 
Ecad+ cells, respectively (Fig. 4D). The Ecad- MHCI- phenotype shared by PDA cells in 
vitro and the DCCs in vivo suggested that the former may be the precursors of the latter. We 
assessed this possibility by intra-splenically injecting 106 Ecad+ and 104 Ecad- cells, 
respectively, into naïve and pre-immunized mice. The growth of Ecad+ macro-metastases in 
the livers of the naïve mice receiving Ecad+ cells was similar to that of naïve mice receiving 
unsorted mM1DTLB cells (Fig. 4E). Microscopic examination of the livers of these mice, 
however, revealed no Ecad- DCCs (Fig. 4F). Injection of Ecad+ cells into pre-immunized 
mice resulted in a rapid decline in photon flux, with no specific signal by day 7 (Fig. 4E), 
and microscopic examination of these livers also demonstrated the absence of DCCs (Fig. 
4F). Injection of Ecad- cells into naïve mice resulted in delayed development of hepatic 
macro-metastases (Fig. 4E), and microscopy revealed the presence of DCCs (Fig. 4F). 
Injection of Ecad- cells into pre-immunized mice led to DCCs but no macro-metastases 
confirming that an on-going T cell response controls DCC outgrowth (Fig. 4E, F). The 
macro-metastases found in naïve mice injected with Ecad- cells were CK19+ (Fig. 4G) and 
MHCI+ (Fig. 4H) indicating reversion to an epithelial phenotype. In summary, the origin of 
the DCC is the Ecad- cell, as DCCs were not present in naïve or pre-immunized mice 
following the injection of Ecad+ cells. Reversion from the quiescent, Ecad- state to the 
proliferating, Ecad+ phenotype is observed in naïve mice, but is masked by the ongoing T 
cell response in pre-immunized mice because reversion is associated with re-expression of 
MHCI. Therefore, the two states of mM1DTLB cells that are observed in vivo--the 
proliferating MHCI+/Ecad+/CK19+ macro-metastasis and the quiescent MHCI-/Ecad-/CK19- 
DCC--occur in vitro, reflecting a developmental plasticity that may be controlled by a cell-
autonomous process.
Unresolved ER stress characterizes PDA cells with the DCC phenotype
To identify the cell-autonomous “switch” regulating the developmental state of the 
metastases, we performed single-cell RNA sequencing (scRNA-seq) of in vitro sorted Ecad+ 
and Ecad- cells. The most upregulated pathway in Ecad- cells relative to Ecad+ cells is 
“Response to ER Stress” (Fig. 5A and S10C), and the most downregulated pathway is “Cell 
Division” (Fig. 5B and S10D). Network analysis of other upregulated pathways that 
distinguish the Ecad- and Ecad+ PDA populations, such as “Autophagy”, shows that they are 
linked to “Response to ER Stress”. Similarly, network analysis of other downregulated 
pathways demonstrates linkage to “Cell Division” (Fig. 5B). These two populations of the 
mM1DTLB PDA cells are also distinct by Principal Component Analysis (PCA), in which 
Ecad- cells appear to be more heterogeneous than Ecad+ cells (Fig. S10A). Indeed, analysis 
at the single-cell level identifies four sub-populations of Ecad- cells, in three of which the 
dominant upregulated pathway is related to “ER stress”, and the major downregulated 
pathway is “Cell Division” (Fig. S11). An EMT signature was not present among the 1639 
genes that were differentially expressed between Ecad+ and Ecad- cells (Fig. S10B), 
confirming the immunofluorescence analysis of Ecad- cells (Fig. S6E). In addition, neither 
Ecad+ nor Ecad- cells express three of the four major NKG2D ligands, Ulbp1, H60b and 
H60c, and both strongly express the inhibitory ligand, Qa1, providing an explanation for the 
absence of a role for NK cells in controlling outgrowth of macro-metastases (Fig. S7C) (30). 
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Genes that are involved in the processing of MHCI were not differentially expressed, which 
is consistent with reports that the ER stress response suppresses the expression of MHCI by 
a post-transcriptional mechanism (31, 32). Finally, support for the conclusion that the ER 
stress response alters the expression of MHCI and Ecad is the finding that treatment of 
mM1DTLB PDA cells with tunicamycin, an inducer of ER stress, increased the proportion 
of cells that were MHCI- and Ecad- (Fig. S12).
The most differentially expressed gene was Ddit3/CHOP, the mRNA level of which was 18-
fold higher in Ecad- cells than in Ecad+ cells. This gene encodes a transcription factor, 
C/EBP homologous protein (CHOP) that is part of the ER stress response. We examined the 
expression of CHOP protein by immunofluorescence in the Ecad- DCCs in human and 
mouse PDA. Anti-CHOP staining was demonstrated in hepatic DCCs in pre-immunized 
mice (Fig. 5C) and in KPCY mice (Fig. 5D), but not in PDA cells of macro-metastases of 
naïve mice or of micro-metastases of KPCY mice (Fig. 5E). Importantly, DCCs in the livers 
of 3/5 patients with PDA also stained with anti-CHOP antibody (Fig. 5E).
The higher expression level of CHOP in DCCs versus in growing PDA cells with an 
epithelial phenotype suggested that the response of DCCs to ER stress was not as effective 
as the response of growing CK19+/Ecad+/MHCI+ PDA cells. To restore protein 
homeostasis, cells undergoing ER stress activate the unfolded protein response (UPR) (33, 
34)). CHOP is induced by the protein kinase RNA-like endoplasmic reticulum kinase 
(PERK) pathway of the UPR (33, 34), and, indeed, this pathway is activated in both Ecad+ 
and Ecad- cells, as shown by phosphorylation of PERK and EIF2α (Fig. S14A). In contrast, 
the Inositol-requiring kinase 1 (IRE1α) pathway is activated in Ecad+ cells but not in Ecad- 
cells, as shown by phosphorylation of IRE1α and splicing of the Xbox binding protein 1 
(XBP1) transcription factor mRNA (Fig. S14A). Impaired activation of the IRE1α pathway 
in Ecad- cells was supported by scRNA-seq results showing decreased expression of XBP1 
target genes relative to their expression levels in Ecad+ cells (Fig. S14B). The cancer cells in 
primary PDA tumors in patients and hepatic macro-metastases in mice also demonstrated 
phosphorylation of both EIF2α and IRE1α, but hepatic DCCs in patients and mice stained 
only with anti-pEIF2α (Fig. 6A-D). Thus, DCCs may not be able to resolve the ER stress 
response because they do not activate the IRE1α pathway, which is required to generate the 
spliced, active form of XBP1 (XBP1s) that regulate the transcription of multiple proteins 
that promote protein folding in the ER.
To determine a whether this unresolved ER stress of DCCs contributes to their phenotype, 
we treated mM1DTLB PDA cells with the chemical chaperone, 4-phenylbutyrate (4-PBA), 
which binds to solvent-exposed hydrophobic segments of unfolded or improperly folded 
proteins, thereby “protecting” them from aggregation and relieving ER stress (35). 4-PBA 
treatment decreased the proportion of cells lacking expression of Ecad (Fig. S15A), and 
increased MHCI expression in both Ecad+ and Ecad- cells (Fig. S15B). We also assessed the 
effect of 4-PBA on the proliferative capability of mM1DTLB PDA cells by first eliminating 
proliferating mM1DTLB PDA cells by treatment with GcV, and then pulsing the residual 
quiescent cells with EdU overnight in the presence or absence of 4-PBA. Relieving ER 
stress with 4-PBA increased the proportion of cells incorporating EdU by 10-fold (Fig. 
S15C). We extended the analysis to DCCs by administering 4-PBA to pre-immunized mice, 
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beginning on the day of the mM1DTLB cell injection and continuing for three weeks. This 
treatment decreased the number of hepatic DCCs by 4-fold relative to the number in control 
mice (Fig. S15D), consistent with the possibility that promoting the conversion of DCCs to 
replicating, MHCI+ cells leads to their T cell-mediated immune elimination. To confirm this 
interpretation, we began 4-PBA treatment of pre-immunized mice three weeks after the 
intra-splenic injection of mM1DTLB cells and depleted the mice of T cells. Within two 
weeks of 4-PBA treatment, all mice had developed MHCI+ macro-metastases (Fig. S15E, 
F), and the number of macro-metastatic lesions in the livers of 4-PBA-treated, T cell-
depleted mice was 6-fold higher than the number in the livers of mice subjected only to 
depletion of T cells (Fig. S15E).
We also assessed the role specifically of the IRE1α pathway in generating PDA cells with 
the DCC phenotype. In a loss-of-function experiment, mM1DTLB cells were treated with 
the IRE1α inhibitor, Kira6 (36), which converted the mM1DTLB cells from an Ecad+, 
MHCI+ state to an Ecad-, MHCI- phenotype in a dose responsive manner (Fig. S14C). We 
then performed gain-of-function experiments with the mM1TetXBP1s cell line expressing a 
doxycycline (Dox) inducible form of XBP1s. This allowed us to test the hypothesis that 
circumventing the defect in IRE1α activation by expression of the spliced form of XBP1 
would resolve ER stress in a more specific and physiological manner than was achieved with 
4-PBA (Fig. S13). Overnight treatment of mM1TetXBP1s cells with Dox induced the 
expression of XBP1s and almost eliminated the Ecad-, MHCI- sub-population (Fig. S14D). 
To examine the role of the IRE1α pathway in DCCs in vivo, pre-immunized mice were 
continuously treated with Dox beginning on the day that mM1TetXBP1s cells were injected 
intra-splenically. After three weeks, the frequency of hepatic DCCs was significantly 
decreased relative to their frequency in control mice not treated with Dox (Fig. 6E). The 
possibility that this decrease in XBP1s-expressing hepatic DCCs indicated killing by 
immune T cells was confirmed by repeating the experiment with the additional intervention 
of T cell-depletion. Within three weeks of Dox-induced XBP1s expression in the DCCs, 9 of 
10 T cell-deficient mice had developed hepatic macro-metastases whereas only 1 of 8 of the 
T cell-depleted mice without Dox treatment developed these lesions (Fig. 6F). Furthermore, 
the number of macro-metastatic lesions in the livers of Dox-treated, T cell-depleted mice 
was 7-fold higher than in the livers of mice subjected only to depletion of T cells (Fig. 6G). 
These results lead us to conclude that unresolved ER stress has a non-redundant, cell-
autonomous role in the maintenance of quiescent, immune-resistant DCCs.
Discussion
This clinical observation that PDA metastases develop in the majority of patients following 
the surgical removal of their primary tumors, despite no evidence of metastases at the time 
of surgery, indicates that these patients had harbored latent metastatic lesions. The nature of 
these latent metastases was suggested by our finding of single DCCs in the livers of patients 
and KPCY mice with PDA that have a distinctive phenotype of absent CK19, Ecad, and 
MHCI. The absence of two typical markers of epithelial ductal adenocarcinoma cells, 
without the occurrence of characteristic markers of EMT, indicates that these DCCs are 
distinct from the PDA cells that comprise growing macro-metastases (37). Moreover, the 
absence of MHCI implies an unusual relationship of DCCs to the adaptive immune system 
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(38), as previously suggested studies of in breast, stomach and colon carcinoma (12, 39). 
These descriptive findings provided the rationale for developing a mouse model that 
replicates DCCs with this distinctive phenotype and allows mechanistic studies defining 
both the cell-autonomous response responsible for the phenotype and the role of the immune 
system.
We hypothesized that metastases in patients with PDA may occur in the context of a cancer-
specific adaptive immune response (20–23). The absence of MHCI expression at the surface 
of DCCs in human and mouse PDA, and the absent or relatively infrequent occurrence of 
hepatic macro-metastases raised the possibility that immunity prevents the outgrowth of 
macro-metastases while ignoring MHCI- DCCs. This prediction was based also on the 
observation that DCCs in human and mouse PDA, in contrast to cancer cells in macro-
metastases, were quiescent. The finding that pre-existing immunity prevented the occurrence 
of hepatic macro-metastases while permitting the seeding of non-replicating, MHCI- hepatic 
DCCs verified this prediction, and provided a potential explanation of how quiescent 
metastases can persist in the presence of an adaptive immune response that is capable of 
suppressing the growth of macro-metastases.
This selective effect of adaptive immunity on macro-metastases required that the cell-
autonomous mechanism that is responsible for the phenotype of DCCs invariably links the 
expression of MHCI to a capacity for cellular replication. This association was not only 
demonstrated in additional cell lines from primary and metastatic PDA tumors from KPC 
mice, but also was supported by the finding that ER stress, which inhibits MHCI expression 
(31, 32) and cell division (40) were the major up-regulated and down-regulated 
transcriptional signatures that distinguish Ecad- cells from Ecad+ PDA cells. Thus, MHCI 
expression is “off” in quiescent cells and “on” in replicating cells. In addition, if the 
markedly increased expression in Ecad- PDA cells of CHOP, a transcription factor that is 
induced by the PERK pathway of the UPR (33, 34), is taken as an indicator of the ER stress 
response, then the finding that in human and mouse PDA, hepatic DCCs are MHCI-, Ki67- 
and CHOP+ links quiescence and immune concealment to an ongoing, unresolved ER stress 
in vivo. Our results confirm the previous suggestion that sustained activation of the UPR 
allows persistence of DCCs in the bone marrow of breast cancer patients (41), and may be 
related to the recent observation that knock-down of IRE1α inhibits tumor growth (42). We 
showed that resolution of ER stress by a chemical chaperone or, more definitively, by the 
induced expression of XBP1s cause reversion of DCCs to an epithelial, proliferating, MHCI
+ phenotype. Thus the DCC phenotype was caused by unresolved ER stress secondary to a 
block in IRE1α activation. Our study does not address how PDA cells avoid activating 
IRE1α, but other studies suggest that under high ER stress, IRE1α acquires endonucleolytic 
activity against RNA targets in addition to the mRNA encoding XBP1 in a reaction termed, 
regulated IRE1-dependent decay of mRNA (RIDD) (43). These additional endonucleolytic 
events may be associated with apoptosis, so that the ability of the PDA cell to adopt the 
DCC phenotype may not only protect it from death caused by immunity, but also death by 
the RIDD reaction.
A latent capacity of hepatic DCCs for reversion to growing cancer cells was revealed by the 
outgrowth of macro-metastases following the depletion of T cells. This finding also implied 
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that T cells eliminated those DCCs spontaneously reverting to a replicating, MHCI+, 
epithelial phenotype. T cell killing of reverting DCCs must be efficient and occur before an 
immune suppressive microenvironment is established since no macro-metastases were 
observed during a 12 month period of observation of T cell-replete mice with hepatic DCCs. 
The causal link between reversal of ER stress in the DCC to a replicating, MHCI+, epithelial 
phenotype was established by the use of the chemical chaperone, 4-PBA, and by the induced 
expression of XBP1s in DCCs. Relief of ER stress by each intervention enhanced the 
expression of Ecad and MHCI and the proliferation by DCCs in vitro, and, more 
importantly, caused the outgrowth of macro-metastases from DCCs in T cell-depleted mice. 
This observation, coupled with the capacity of 4-PBA and XBP1s to decrease hepatic DCCs 
in T cell-replete mice, supports the essential role of unresolved ER stress response in 
maintaining the DCC phenotype. Other factors, such as CXCR2 (C-X-C chemokine receptor 
type 2)-expressing neutrophils, may also have a role in this response (44).
The implications for therapy to prevent the occurrence of metastatic disease in patients 
following the surgical removal of their primary PDAs may be two-fold. First, outgrowth of 
latent DCCs in the mouse model requires suppression of T cell immunity. Elevations of 
plasma cortisol following pancreatectomy in patients with PDA (45) are in the range that 
was found to be immune suppressive in cachectic mice with PDA (46). This stimulation of 
the hypothalamic-pituitary-adrenal axis may also occur with the caloric deprivation that 
commonly occurs in patients after this surgical procedure (47). Therefore, post-operative 
parenteral hyper-alimentation may be an effective means to decrease the occurrence of 
metastatic disease in patients following surgical removal of their primary PDAs. Second, and 
more speculative, the administration of a chemical chaperone, like 4-PBA, pre-operatively 
when tumor immunity is intact might purge organs of latent DCCs, thereby decreasing the 
likelihood of post-operative metastatic disease.
Material and Methods
Animals
Male C57Bl/6 mice 10 to 12 weeks of age purchased from The Jackson Laboratory were 
used. All procedures were approved by the Cold Spring Harbor Laboratory Institutional 
Animal Care and Use Committee (IACUC) and were conducted in accordance with the NIH 
“Guide for the Care and Use of Laboratory Animals”.
Cell culture
Cell lines used in that study were a gift of Dr. David Tuveson (Cold Spring Harbor 
Laboratory). The metastatic cell line mM1 and the primary cells line 1242 were derived 
from a KPC mice liver metastasis and a primary tumor, respectively. Cells were cultured in 
DMEM medium (#10–013-CV, Cellgro) supplemented with 10% fetal calf serum (FCS) 
(#1500–500, Seradigm), 100 units/mL penicillin, and 100 μg/mL streptomycin.
Human samples
Postmortem tissues were obtained following the Iacobuzio-Donahue laboratory rapid 
autopsy program previously described in detail (48). Patients were selected based on two 
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criteria: p53 loss-of-heterozygosity, which allowed the staining for accumulation of mutant 
p53 protein, and absence of clinically detectable liver metastases.
Cell culture reagents
Ganciclovir (GcV, Sigma-Aldrich #G2536), was used at concentration ranging from 1–
100mM. Tunicamycin (#11445, Cayman chemicals) was used at 5μg/ml. Sodium 4-
Phenylbutyrate (4-PBA, #11323, Cayman chemicals) was used at 5mM. 5-Ethynyl-2’-
deoxyuridine (EdU, #sc-284628, Santa Cruz biotechnology) was used at 10mM.
EdU labelling
For short term EdU pulse, mice were injected every 12 hours with 1.4 mg of EdU over a 3-
day period. For long term experiments, EdU was given in the drinking water at 0.82 mg/ml 
+ 2.5% sucrose. Revelation of EdU containing cells was performed with a kit (Click-iT™ 
Plus EdU Imaging Kit, Molecular probes, #C10640) following the manufacturer protocol.
CFSE labelling
Cells were harvested from the cell culture and CFSE (CellTrace™ CFSE Cell Proliferation 
Kit, Molecular probes, #C34554) was used according to the manufacturer protocol.
Immune cells depletion
200μg of anti-CD4 (clone GK1.5, BioXcell) and/or anti-CD8 (clone 53.6–7, BioXcell) or 
anti-NK1.1 (clone PK136, BioXcell) were injected intraperitoneally 2 times a week.
Antibodies for immunofluorescence and flow cytometry
Antibody Clone or Cat. # Provider Dilution
GFP D5.1 Cell signaling technology 1/100
CK19 (mouse and human) EP1580Y Abcam 1/300–1/1000
Ki67 (mouse) #NB500–170 Novus 1/100
Ki67 (human) #ab15580 Abcam 1/800
MHCI M¼2 Biolegend 1/100
CD3 17A2 Biolegend 1/100
CD8 53.6–7 Biolegend 1/50
E-cadherin Decma-1 Biolegend 1/200
Firefly Luciferase #200–101-C44 Rockland 1/200
CHOP 9C4 Novus 1/100
Desmin #ab15200 Abcam 1/200
aSMA 1A4 Abcam 1/200
Snail1 C15D3 Cell signaling technology 1/50
Slug C1967 Cell signaling technology 1/50
NKp46 29A1.4 Biolegend 1/100
CD45 30-F11 Novus 1/100
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Antibody Clone or Cat. # Provider Dilution
F4/80 BM8 Biolegend 1/100
CD19 1D3 Biolegend 1/100
CD31 390 Molecular probes 1/50
p53 (human) DO1 Invitrogen 1/100
MHCI (human) HCA2 Acris 1/100
Donkey anti-Goat #A-11055 Life technologies 1/500
Donkey anti-Rabbit #A-31573 Life technologies 1/500
Donkey anti-Rat #ab175475 Abcam 1/500
Goat anti-mouse #A21424 or A21235 Invitrogen 1/600
pIRE1α (mouse and human) #NB100–2323 Novus biologicals 1/100
pEIF2α (mouse and human) #ab84980 Abcam 1/100
XBP1s #83418 Cell signaling technology 1/1000
pPERK #MA5–15033 ThermoFisher 1/100
Fluorochrome conjugation
For some applications (Ki67 staining in Fig. 1 and CHOP staining in Fig. 5), the anti-p53 
antibody was conjugated using Zenon labeling reagent 555 (Life Sciences, # Z25005) 
following the manufacturer’s protocol.
Chemical chaperone treatment
4-PBA was given to mice in drinking water at 1g/kg/day.
Doxycycline treatment
Dox was given to mice in drinking water at 2mg/ml + 5% sucrose
Plasmid preparation and transfection
For the generation of mM1DTLB PDA cells: Sequences of the genes of diphtheria toxin 
receptor (D), HSV-TK (T), firefly luciferase (L) and mTagBFP2 (B) were generated by gene 
synthesis (Invitrogen GeneArt) with appropriate restriction sites. For HSV-TK and firefly 
luciferase, sequences were digested and migrated with agarose gel electrophoresis. 
Appropriate size bands were purified with gel extraction kit (Qiagen, #28706) and cloned 
into the piggyback transposon vector (PB-EF1-MCS-IRES-Neo cDNA Cloning and 
Expression Vector, System Bioscience #PB533A-2). For mTagBFP2, the sequence was 
amplified by PCR and cloned into the linearized piggyback vector already containing HSV-
TK and firefly luciferase with Gibson assembly master mix (New England Biolabs 
#E2611L). Plasmids were purified using Zippy plasmid miniprep kit (Zymo research, 
#D4037). Cells were transfected with the resulting vector and the plasmid of the super 
piggyback transposase (System Bioscience, #PB210PA-1) with Lipofectamine 3000 
(Thermofisher, #L3000015). Cells were selected for stable transfectant with G418 (Sigma-
Aldrich #A1720) and sorted for the highest expression of mTagBFP2(Fig. S1A). The 
functionality of Luciferase, DTR and HSV-TK was verified in vitro (Fig. S1B and C).
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For the generation of mM1TetXBP1s PDA cells: The sequence of spliced XBP1 (XBP1s) 
and mCherry linked by a 2A peptide sequence was generated by gene synthesis (Genscript) 
with appropriate restriction sites. The sequence was digested and migrated with agarose gel 
electrophoresis. Appropriate size bands were purified with gel extraction kit (Qiagen, 
#28706) and cloned into an inducible TetON plasmid (gift of Dr. Scott Lyons). Plasmids 
were purified using Zippy plasmid miniprep kit (Zymo research, #D4037). mM1DTLB PDA 
cells were transfected with the resulting vector with Lipofectamine 3000 (Thermofisher, 
#L3000015). Cells were selected for stable transfectant with puromycin (Sigma-Aldrich 
#P8833) and sorted first for no mCherry expression without doxycycline (Dox) to remove 
cells with potentially leaking expression and then for the highest expression of mCherry 
upon Dox treatment to select inducible cells (Fig. S13A). Tight inducible over-expression of 
XBP1s was confirmed in vitro by western blot analysis (Fig. S13B).
Generation of pre-immunized mice
Mice were anesthetized by isoflurane and dorsal fur was removed with a clipper. A sub-
cutaneous injection of 106 PDA cells was performed. Tumors were grown for 2 weeks. In 
order to eliminate the tumors, diphtheria toxin (DTx, List Biologicals, #150) was injected 
intraperitoneally on two consecutive days at a dose of 25ng/g. GcV was injected 
intraperitoneally on two consecutive days at a dose of 0.3mg/g. In approximately 20% of the 
cases, one round of DTx and GcV injection was not sufficient to eliminate the tumors, and a 
second round of injection was performed one week later. On rare instances two rounds of 
injections were insufficient, and these animals were not used. The absence of remaining 
cancer cells was confirmed by bioluminescence (Fig. S1D) and mice were used for 
experiments at least three weeks after the last injection of DTx and GcV.
Pancreatic cancer metastasis model
For the liver metastasis model, animals were anesthetized by isoflurane, a 1 cm incision was 
made in the left subcostal region and the spleen was exposed. A suspension of 106 
pancreatic cancer cells in 50 μl of PBS was injected into the body of the spleen. Immediately 
following injection, mice were splenectomized to prevent growing of extra-hepatic tumors. 
The peritoneum was closed with a 5–0 absorbable surgical suture (Vicryl, Ethicon) and the 
skin with wound clips (Roboz surgical instruments). For the lung metastasis model 106 cells 
in 100 μl were injected through the tail vein.
Bioluminescence imaging
Mice were anesthetized by isoflurane and ventral fur was removed with a clipper. 150 μl of a 
30mg/ml D-Luciferin K+ salt (Perkin-Elmer, #122799) solution was injected 
intraperitoneally. Mice were imaged with an IVIS Spectrum in Vivo Imaging System 
(Perkin-Elmer) 14 min after the injection.
Immunofluorescence
Organs were harvested and fixed with PLP buffer (1% PFA, 80mM L-lysin, 10mM NaIO4); 
through portal vein perfusion in the case of livers. Organs were embedded in Tissue-Tek 
OCT compound (Sakura, #4583) and section of 10 μm were cut on a Leica cryostat. 
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Between each of the following steps, sections were washed three times for five min with 
PBS. Tissue sections were post-fixed for 15min at room temperature with PLP buffer and 
permeabilized for 15min at room temperature with 0.1% Triton X100 in PBS for mouse 
tissues or 30min at room temperature with 0.2% Triton X100 in PBS for human tissues. 
Sections were surrounded with hydrophobic barrier pen (ImmEdge, Vector labs, #H-4000) 
and unspecific antibody labelling was blocked for 1hr at room temperature with 10% donkey 
serum (Jackson immunoresearch, #017–000-121) in PBS for mouse tissues or 10% goat 
serum (Thermo Fisher, #16210–064) in PBS for human tissues. Primary antibodies were 
incubated overnight at 4 °C in the dark. Secondary antibodies were incubated for 2hr and 
room temperature in the dark. Nuclei were counterstain with dapi (Molecular probes, 
#R37606) for 10 min at room temperature in the dark and sections were mounted with 
ProLong diamond antifade mountant (Molecular probes, #P36965) for mouse tissues or 
ProLong gold antifade mountant (Molecular probes, #P36934). Images were acquired using 
a spinning disk confocal microscope (Perkin-Elmer UltraVIEW VoX, High speed spinning 
disk Yokogawa® CSU-X1) with 20X or 60X objectives. Images were analyzed with ImageJ. 
CFSE (CellTrace™ CFSE Cell Proliferation Kit, Molecular probes, #C34554) and EdU 
(Click-iT™ Plus EdU Imaging Kit, Molecular probes, #C10640) staining were performed 
following the manufacturer protocol.
Flow cytometry analysis and sorting
Cells were harvested with TrypLE (Gibco, #12605036), distributed in 96-well round-bottom 
plate and centrifuged at 2000 rpm for 1 min at 4 °C. Supernatant was removed and the cells 
incubated in ice cold FACS Buffer (1% FBS and 0.02% Sodim Azide in PBS) with Fc Block 
(Biolegend clone 93) at 4 °C for 15 min. After a wash in FACS Buffer, the cells were 
incubated with primary and secondary antibodies for 15 min at 4 °C in the dark. The cells 
were then washed twice in FACS Buffer and resuspended in 450 ml PBS before analysis 
using a LSR Fortessa (BD Biosciences) operated by a FACSDIVA (BD Biosciences) 
software. Data analysis was performed on FlowJo 10 (FlowJo, LLC). For sorting, cells were 
submitted to the same procedure as for flow cytometry analysis and processed using BD 
FACSAria (BD Biosciences).
Disseminated cancer cell count
Sections were taken every 100μm through the entire thickness of the liver. The thickness of 
the liver was measured at the same time. DCCs were identified by luciferase expression and 
counted in every section. The number of DCCs per whole liver was then calculated.
scRNAseq
scRNA libraries were generated from viable Ecad+ and Ecad- tumor cells obtained by flow 
cytometry sorting. PDA cells were adjusted to 200 cells/μL and applied to the C1 system for 
single-cell capture with a 10–17μm IFC (Fluidigm). In the C1, whole-transcriptome 
amplification was performed with the SMARTer kit (Clontech), and the product was 
converted to Illumina sequencing libraries using Nextera XT (Illumina). RNA-seq was 
performed on a NextSeq instrument (Illumina) single read 75. Quality control was 
performed using FastQC and cells with low read numbers were eliminated. Reads were 
aligned against reference mouse genome (EnsMart72) and transcript expression values were 
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determined after transcript normalization (transcript per million; TPM) with AltAnalyze. 
Cells with aberrant expression for Gapdh, Actb and Hprt were eliminated leaving 104 Ecad+ 
and 98 Ecad- cells for further analysis. Transcripts were considered significantly expressed if 
TPM ≥ 1. Differential expression analysis was performed considering fold-change between 
Ecad+ and Ecad- cells ≥ 2 fold as a cut-off. Pathway enrichment analysis and network maps 
were performed with Cytoscape v3.5.1 and the ClueGo v2.3.3 plugin. Pathways with p<0.01 
after Benjamini-Hochberg procedure for false discovery rate were considered significant.
Statistical analysis
Two column comparisons were performed with an unpaired t test. Comparison of three or 
more columns was analyzed using a one-way ANOVA followed by Tukey’s procedure. A p-
value less than 0.05 was considered significant, ***p<0.001, **p<0.01 and *p<0.05. All 
statistical analyses were performed using GraphPad Prism software version 6.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Single DCCs with a characteristic phenotype are present in the livers of humans and mice 
with PDA.
(A-C) Immunofluorescence (IF) of sections from the primary tumor and liver of a patient 
with PDA that have been stained with anti-p53 to reveal cancer cells (red) and (A) anti-
CK19 (green), (B) anti-Ki67 (green) or (C) anti-MHCI (green). Photomicrographs are 
representative of five patients. (D-F) IF of sections from a liver of a KPCY mouse with 
spontaneous PDA and no hepatic macro-metastases. Sections were stained with anti-YFP to 
reveal cancer cells (green) and (D) anti-CK19 (red), (E) anti-Ki67 (red), and (F) anti-MHCI 
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(red). Photomicrographs are representative of three mice. The ratios shown in the top right 
corners of the photomicrographs represent the frequency of the observed DCC phenotype 
relative to the total number of DCCs that were assessed. All frequencies are compiled in 
table S2. White arrows designate DCCs and, in the sections of human livers, green arrows 
designate normal, liver-resident CK19+ or MHCI+ cells. Scale bar = 25μm.
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Fig. 2. A mouse model for hepatic DCCs.
(A) Mice are pre-immunized by subcutaneous injection of 106 mM1DTLB PDA cells 
derived from a hepatic metastasis of a KPC mouse. After two weeks, tumors are eliminated 
by treating mice with DTx and GcV. For hepatic metastases, 106 mM1DTLB PDA cells are 
injected intra-splenically into naïve and pre-immunized mice, followed immediately by 
splenectomy. (B, C) Tumor growth was measured by whole body bioluminescence imaging. 
(D) Ex vivo photon flux of whole livers was measured at day 5, 10, 15 and 20 after cancer 
cell injection. Results are representative of three experiments with at least five mice per 
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group. Dashed gray line represents the background luminescence in tumor-free mice. (E-J) 
IF of sections from a liver of a naive mouse (left panels) or a pre-immunized mouse (right 
panels) that have been stained with anti-luciferase (green) to identify cancer cells and (E) 
anti-CK19 (red), (F) anti-Ecad (red), (G) anti-Ki67 (red), (H) EdU (red), (I) anti-MHCI 
(red), and (J) CD3 (red). For EdU staining, mice were injected every 12 hours with EdU for 
three days. Photographs are representative of 20 mice from three independent experiments. 
The ratios shown in the top right corners of the photomicrographs represent the frequency of 
the observed DCC phenotype relative to the total number of DCCs that were assessed. All 
frequencies are compiled in table S2. White arrows designate DCCs. Scale bar = 25μm.
Pommier et al. Page 20
Science. Author manuscript; available in PMC 2019 June 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. T cells control outgrowth of latent DCCs.
(A) The growth of hepatic metastases in pre-immunized mice that had been depleted of T 
cells by administration of antibodies to CD4 and CD8 beginning at three weeks or nine 
weeks after splenic injection of mM1DTLB PDA cells was assessed by bioluminescence 
imaging. One group of mice was also treated with isotype control antibody. (B and C) IF of 
sections containing macro-metastases from a liver of a pre-immunized mouse that had been 
depleted of T cells three weeks after splenic injection of mM1DTLB PDA cells. Anti-
luciferase identifies cancer cells. Scale bar = 25μm.
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Fig. 4. A subpopulation of PDA cells in vitro shares phenotypic features with DCCs.
(A) Flow cytometry analysis of mM1DTLB PDA cells that have been stained with anti-
CK19 or anti-Ecad. Results are representative of five independent experiments. (B) Flow 
cytometry measurement of anti-MHCI staining of Ecad+ and Ecad- mM1DTLB PDA cells, 
and of lymph node cells as a comparator. Results are representative of five independent 
experiments. (C) mM1DTLB PDA cells were treated in vitro for 48h with increasing doses 
of GcV to kill proliferating cells, and the proportion of viable cells that was Ecad-/MHCI- 
was measured by flow cytometry. Results are representative of two independent 
experiments. **=p<0.01, ***=p<0.001. (D) FACS analysis of purified Ecad+ and Ecad- 
mM1DTLB PDA cells, respectively, that have been cultured for three days. Dot plots (left 
panel) and histograms (right panel) are representative of three independent experiments. (E) 
Growth of hepatic metastases after intra-splenic injection of 106 Ecad+ or 104 Ecad- 
mM1DTLB PDA cells into naïve and pre-immunized mice was assessed by whole body 
bioluminescence imaging. n=5 mice per group. Dashed gray line represents the 
luminescence background in tumor-free mice. (F) Table summarizing the occurrence of 
DCCs and/or metastases in each group of mice thai had been injected with Ecad+ or Ecad- 
mM1DTLB cells. (G and H) IF of sections from a liver of a naïve mouse that had received 
an intra-splenic injection of Ecad- mM1DTLB cells. Anti-luciferase (green) identifies cancer 
cells. Photomicrographs are representative of five mice. Scale bar=25μm.
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Fig. 5. The ER stress response in PDA cells that share phenotypic features of DCCs.
104 Ecad+ and 98 Ecad- mM1DTLB PDA cells were subjected to single-cell RNA-Seq. (A) 
Network analysis, following pathway enrichment analysis, shows ontology relationships 
between the pathways (left panel). Their relative representation is depicted as a pie chart 
(right panel) for (A) Upregulated pathways and (B) Downregulated pathways in the Ecad- 
cells relative to Ecad+ cells. Pathways are significant with an adjusted p<0.01 after 
Benjamini-Hochberg false discovery rate. (C) Liver sections from a naive mouse and a pre-
immunized mouse were stained with anti-luciferase (green) to identify PDA cells and anti-
CHOP (red) to identify cells exhibiting an ER stress response. (D) Liver sections from a 
KPCY mouse were stained with anti-YFP (green) to identify PDA cells and with anti-CHOP 
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(red). (E) Sections from the primary tumor and liver of a patient with PDA were stained with 
anti-p53 to identify PDA cells (red) and with anti-CHOP (green). Photomicrographs are 
representative of five patients who had no detectable liver metastases. The ratios shown in 
the top right corners of the photomicrographs represent the frequency of the observed DCC 
phenotype relative to the total number of DCCs that were assessed. All frequencies are 
compiled in table S2. White arrows designate DCCs. Scale bar = 25μm.
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Fig. 6. Absence of IRE1α pathway activation in DCCs.
(A) Liver sections from naive and pre-immunized mice were stained with anti-luciferase 
(green) to identify PDA cells and anti-pEIF2α (red) to assess activation of the PERK 
pathway. (B) Sections from the primary tumor and liver of a patient with PDA were stained 
with anti-p53 to identify PDA cells (green) and anti-pEIF2α (red). (C) Liver sections from 
naive and pre-immunized mice were stained with anti-luciferase (green) to identify PDA 
cells and anti-pIRE1α (red). (D) Sections from the primary tumor and liver of a patient with 
PDA were stained with anti-p53 to identify PDA cells (green) and anti-pIRE1α (red). 
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Photomicrographs are representative of five patients who had no detectable liver metastases. 
The ratios shown in the top right corners of the photomicrographs represent the frequency of 
the observed DCC phenotype relative to the total number of DCCs that were assessed. All 
frequencies are compiled in table S2. White arrows designate DCCs. Scale bar = 25μm. (E) 
Pre-immunized mice (n=5) that had received splenic injections of mM1TetXBP1s PDA cells 
were treated with Dox starting on the day of injection. The number of hepatic DCCs was 
determined three weeks later and compared to that of mice not receiving Dox (n=5). (F) Pre-
immunized mice that had received splenic injections of mM1TetXBP1s PDA cells were 
treated (n=10) or not treated (n=8) with Dox beginning three weeks later. T cells were 
depleted by administering anti-CD4 and anti-CD8 antibodies. Growth of hepatic metastases 
was assessed by whole body bioluminescence imaging (G) The mean number of 
bioluminescent metastases formed with or without Dox treatment was determined in 
resected livers. ** = p<0.01, *** = p<0.001.
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